Background Better outcome with the PCI, but in-stent restenosis (ISR) compromises the long-term results PCI is the most frequently used method for revascularization As a consequence, the prevention and treatment of ISR have become priorities in interventional cardiology !
Background The use of DES is the most effective way to reduce ISR according to randomized trials in selected patient groups However, there is no evidence that BMS or DES could influence mortality or prevent MI Recently, growing concern has been expressed about the safety of DES most notably with respect to late Stent Thrombosis As a result, some cardiologists have tended to revert to more predictable devices e.g., BMS or stents that are coated with active compounds , such as titanium-nitride-oxide
Bio Active Stent (BAS) TITAN ® - stent by Hexacath (France) TITANOX Coating (Titanium-Nitride-Oxide) Nitrogen, Oxygen and Titanium atoms are bounded with electronic and atomic links. (L.Pauling classification) < 1mm Crimped profile 70-90 MICRONS Strut thickness 316L+TITANOX COATING Material HELICOIDAL DESIGN Stent geometry
Bio Active Stent in Finland Helistent ® Hexacath, Fra 2002 Titan ® Stent in Finland August 2002 First Treated Patient in PORI May 2003 PORI stent registry May 2003 – Nov 2004 TITAX AMI Nov 2005- Nov 2006 Pori Stent Registry Eurointerv. 2006 J Invasive Cardiol. 2006 TCT2005, TCT2006 TITAX AMI trial EuroPCR2007 Late Breaking Trials TCT2007 Karjalainen P, et al. J Invasive Cardiol 2006;18:462-468